Fujifilm Strengthens Life Sciences Leadership Across Biomanufacturing and iPSC Businesses
FUJIFILM Holdings America Corporation has announced expanded leadership responsibilities for three senior executives across its Life Sciences Group, reinforcing the company’s strategic focus on cell therapy, biologics manufacturing, and induced pluripotent stem cell (iPSC) technologies. The leadership updates span multiple subsidiaries, including FUJIFILM Biotechnologies California and FUJIFILM Cellular Dynamics, and are designed to strengthen operational alignment across Fujifilm’s growing end-to-end life sciences ecosystem.
The changes reflect Fujifilm’s continued investment in advanced therapeutic manufacturing capabilities and its broader ambition to support the next generation of cell and gene therapies, regenerative medicine platforms, and New Approach Methodologies (NAMs) used in drug discovery.
Expanded Leadership Role for Tomoyuki Hasegawa
A central element of the announcement is the expanded leadership scope of Tomoyuki Hasegawa, a long-tenured Fujifilm executive with more than 25 years of experience across multiple global roles within the organization in both Japan and the United States.
Hasegawa will now serve as Chief Executive Officer of FUJIFILM Biotechnologies California, a contract development and manufacturing organization (CDMO) specializing in biologics and advanced therapies. In addition to this new role, he will continue to hold dual leadership responsibilities as General Manager of the Fujifilm Life Sciences Strategic Office and Chairman and CEO of FUJIFILM Cellular Dynamics, a global leader in iPSC technology development and manufacturing.
His expanded portfolio places him at the center of Fujifilm’s efforts to integrate biologics manufacturing with next-generation cell therapy capabilities. The alignment is expected to enhance coordination across the company’s life sciences businesses, enabling more streamlined support for partners developing complex therapies.
Over the past four years, Hasegawa has played a key role in advancing FUJIFILM Cellular Dynamics’ innovation strategy in regenerative medicine and life sciences. Under his leadership, the company has expanded its technological capabilities, strengthened partnerships across the pharmaceutical and biotechnology sectors, and contributed to the growing adoption of iPSC-derived models in drug discovery and translational research.
Expansion of iPSC Manufacturing Infrastructure
A key milestone highlighted in the announcement is the recent opening of FUJIFILM Cellular Dynamics’ new headquarters and manufacturing facility in Madison, Wisconsin. The site is designed to support the company’s expanding portfolio of iPSC-based research products and services.
The facility significantly increases manufacturing capacity and enhances Fujifilm’s ability to support demand for advanced cell-based research tools. It also strengthens the company’s role in providing scalable solutions for regenerative medicine research and therapeutic development.
The company’s iCell product line, derived from human iPSCs, is increasingly being used in New Approach Methodologies (NAMs)—innovative non-animal research models that are gaining traction in pharmaceutical development and regulatory science. These tools are being adopted for applications in toxicity testing, disease modeling, and early-stage drug discovery, reflecting a broader industry shift toward more predictive and human-relevant research systems.
The expansion of iPSC infrastructure underscores Fujifilm’s commitment to building capabilities that support both research and clinical translation in regenerative medicine and cell therapy development.
New Leadership Role for Delara Motlagh
Alongside Hasegawa’s expanded responsibilities, Fujifilm also announced that Delara Motlagh, currently Chief Operating Officer of FUJIFILM Cellular Dynamics, will assume the additional role of President of the company.
Since joining FUJIFILM Cellular Dynamics in April 2025, Motlagh has overseen business operations, strategic planning, and execution across both discovery research and cell therapy CDMO business units on a global scale. Her promotion to President reflects her expanding leadership role in guiding the company’s operational and commercial direction.
Motlagh brings more than two decades of experience in the life sciences and biopharmaceutical industries, with a strong background in cell and gene therapy, manufacturing operations, and strategic business development. Prior to joining Fujifilm, she held senior leadership positions at several major healthcare and life sciences companies, including Catalent Pharma Solutions, Terumo Blood and Cell Technologies, and Baxter Healthcare.
Her experience spans multiple functional areas, including research and development, commercial operations, marketing, and business strategy. This cross-functional expertise is expected to support FUJIFILM Cellular Dynamics as it continues to expand its global footprint in iPSC-based research services and cell therapy manufacturing.
Strengthening Cell Therapy CDMO Capabilities
In his expanded role, Hasegawa will work closely with David Bolish, the newly appointed Chief Operating Officer of FUJIFILM Biotechnologies California, to further strengthen Fujifilm’s cell therapy CDMO capabilities.
Bolish, who has served as Site Head since 2018, brings more than 20 years of experience in biopharmaceutical manufacturing, engineering, commercialization, and operational strategy. His expertise in scaling manufacturing operations and supporting clinical and commercial production is expected to complement Fujifilm’s growing focus on cell therapy manufacturing services.
Together, Hasegawa and Bolish will focus on enhancing Fujifilm’s ability to deliver integrated CDMO solutions that span the full lifecycle of cell therapy development—from early-stage research and process development through clinical manufacturing and commercial production.
This integrated approach reflects increasing demand from biotechnology and pharmaceutical companies for partners capable of supporting complex cell-based therapies with high-quality, scalable manufacturing infrastructure.
Strategic Vision for Integrated Life Sciences Growth
Toshihisa Iida, Corporate Vice President and General Manager of the Life Sciences Strategy Headquarters and Bio CDMO Division at FUJIFILM Corporation, emphasized that the leadership changes are designed to strengthen alignment across the company’s life sciences businesses.
He noted that Tomoyuki Hasegawa’s extensive experience positions him to bridge Fujifilm’s cell therapy and biologics manufacturing capabilities, enabling a more cohesive and integrated CDMO offering for global partners. This alignment is expected to enhance the company’s ability to deliver end-to-end solutions for customers developing advanced therapies.
Iida also highlighted the importance of Delara Motlagh’s leadership at FUJIFILM Cellular Dynamics at a time when demand for New Approach Methodologies and iPSC-based platforms is increasing across the pharmaceutical and biotechnology industries. He noted that experienced partners in iPSC development are becoming increasingly essential as drug developers seek more predictive and human-relevant models for research and therapeutic innovation.
According to Iida, these organizational enhancements represent a broader investment in scaling Fujifilm’s infrastructure in the United States to support next-generation cell-based research and therapeutic development.
Advancing the “Partners for Life” Philosophy
Fujifilm’s Life Sciences Group operates under the guiding principle of being “Partners for Life,” a philosophy centered on long-term collaboration with biotechnology and pharmaceutical partners to advance healthcare innovation.
The latest leadership changes are intended to reinforce this approach by strengthening internal coordination across business units and enhancing the company’s ability to deliver integrated solutions across the life sciences value chain.
By aligning leadership across FUJIFILM Biotechnologies California and FUJIFILM Cellular Dynamics, the company aims to provide more seamless support for partners developing complex therapies, particularly in areas such as cell therapy, regenerative medicine, and advanced biologics manufacturing.
Positioning for Growth in Cell Therapy and Regenerative Medicine
The global cell therapy and regenerative medicine sectors continue to experience rapid growth, driven by advances in gene editing, stem cell biology, and personalized medicine. As demand increases for scalable manufacturing and reliable cell-based platforms, CDMOs are playing an increasingly important role in supporting therapeutic development.
Fujifilm’s expanded leadership structure reflects its intention to remain a key player in this evolving landscape. By strengthening its expertise in both biologics manufacturing and iPSC technology, the company is positioning itself to support a broad range of applications across research, clinical development, and commercial manufacturing.
The integration of leadership roles across its life sciences businesses is expected to enhance operational efficiency, accelerate innovation, and support the company’s long-term growth strategy in advanced therapeutics.
With expanded leadership roles for key executives, a newly opened iPSC manufacturing facility, and continued investment in cell therapy infrastructure, Fujifilm is reinforcing its position as a global life sciences partner focused on next-generation therapeutic development.
As the industry increasingly shifts toward complex biologics and cell-based therapies, the company’s integrated approach—combining CDMO services, iPSC platforms, and regenerative medicine expertise—positions it to play a central role in supporting innovation across the global biopharmaceutical ecosystem.
Through these strategic leadership enhancements, Fujifilm aims to strengthen its ability to deliver scalable, high-quality solutions that support the development of transformative therapies and advance the future of precision medicine.
About FUJIFILM Biotechnologies California
FUJIFILM Biotechnologies California, a subsidiary of Corporation, specializes in developing and manufacturing cell-based therapeutics. Located in Thousand Oaks, California, the company operates a state-of-the-art cell therapy manufacturing facility featuring cGMP production suites, quality control and development laboratories, and product storage and distribution capabilities.
These facilities support both autologous and allogeneic cell therapy manufacturing while meeting global regulatory standards for advanced therapies and medicinal products. With its highly skilled and experienced workforce and regulatory agency approved manufacturing capabilities,Biotechnologies California is shaping the future of medicine through the advanced production of cell therapies. The company leverages the global network and end-to-end CDMO capabilities of the Life Sciences Group to provide solutions that support complex cell therapy development and manufacturing.
About FUJIFILM Cellular Dynamics, Inc.
FUJIFILM Cellular Dynamics, Inc. is a leading developer and manufacturer of human iPSCs and iPSC-derived cells utilized in drug discovery, contract development and manufacturing services for cell therapies. For its partners, Cellular Dynamics utilizes its iPSC platform to advance the progress of therapeutic candidates in the clinic and provides contract development and manufacturing (CDMO) services.
In addition to cell therapy, Cellular Dynamics also offers life science research tools including the company’s inventoried iCell® products, which are available in almost any cell type and are sourced from multiple cell lines which can be applied for target identification as well as toxicity testing. The company also offers custom cell services and cell banking. Cellular Dynamics’ goal is to leverage the vast utility of iPSCs to advance human health and improve the quality of life for patients around the world. For more information, please visit: www.fujifilmcdi.com
About Fujifilm
FUJIFILM Americas is the regional headquarters for the Americas. It is comprised of 20 group companies across North and Latin America that are engaged in the research, development, manufacture, sale and service of products and services. The company’s portfolio represents a broad spectrum of industries including medical and life sciences, electronic materials, chemical, graphic arts, information systems, industrial products, broadcast, data storage, and photography. For more information, please visit: https://www.fujifilm.com/us/en/about/region.
FUJIFILM Holdings Corporation, headquartered in Tokyo, leverages its depth of knowledge and proprietary core technologies to deliver innovative products and services across the globe through the four key business segments of healthcare, electronics, business innovation, and imaging with over 70,000 employees.
Guided and united by our Group Purpose of “giving our world more smiles,” we address social challenges and create a positive impact on society through our products, services, and business operations. Under its medium-term management plan, VISION2030, which ends in FY2030, we aspire to continue our evolution into a company that creates value and smiles for various stakeholders as a collection of global leading businesses and achieve a global revenue of 4 trillion yen (29 billion USD at an exchange rate of 140 JPY/USD).
